Parenteral nutrition statistics at a glance
Parenteral nutrition sits at the intersection of medicine, logistics, and cost control, and the numbers behind it show why the field draws so much scrutiny. The statistics below trace home parenteral nutrition, hospital use, drug shortages, and neonatal guidance across a dataset that spans clinical recommendations and real-world claims.
Quick takeaways
- Home parenteral nutrition served approximately 32,000 Americans annually between 2022 and 2024 (NHIA Home Parenteral Nutrition Cost White Paper).
- Direct costs for home parenteral nutrition were 32% to 36% lower over 1 week to 1 month than hospital-based care (NHIA Home Parenteral Nutrition Cost White Paper).
- The compounded average cost to prepare a bag of HPN rose 75.4% from 2016 to 2024 (NHIA Home Parenteral Nutrition Cost White Paper).
- FDA tracked 15 new drug shortages in 2024, after a peak of 251 in 2011 (FDA Drug Shortages Report to Congress CY 2024).
- In the Sustain registry, the overall CLABSI rate was 0.87 episodes per 1,000 PN-days across 1,046 HPN patients (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
Table of contents
- What the parenteral nutrition statistics show
- Home parenteral nutrition costs and access
- Drug shortages and supply pressure
- Clinical dosing and nutrition benchmarks
- Infection and complication data
- Home-start and hospital-use patterns
- Why the dataset matters for patients and providers
What the parenteral nutrition statistics show
The strongest pattern in this dataset is not a single number but the way several numbers point in the same direction. Home parenteral nutrition is widely used, clinically important, and expensive to deliver, while shortages and infection control make it operationally fragile.
A second pattern is that the dataset splits cleanly between two worlds: population-scale cost and claims data on one side, and clinical guidance for preterm and ICU patients on the other. That combination makes the keyword broader than a narrow home-infusion topic. It covers treatment delivery, dosing, safety, and the economics of keeping PN available.
At a glance
- Scale: roughly 32,000 Americans annually used home parenteral nutrition between 2022 and 2024 (NHIA Home Parenteral Nutrition Cost White Paper).
- Cost pressure: bag-compounding costs rose 75.4% over the 2016 to 2024 period (NHIA Home Parenteral Nutrition Cost White Paper).
- Claims trend: total monthly payment for a patient on HPN fell 5.47% from 2022 to 2024 (NHIA Home Parenteral Nutrition Cost White Paper).
- Supply stress: home infusion pharmacies submitting HPN claims declined by 15.6% per year over the past 3 years (NHIA Home Parenteral Nutrition Cost White Paper).
- Safety benchmark: Sustain recorded 194 CLABSI events over 223,493 days of HPN exposure (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
Big picture: the dataset shows a therapy that can lower direct care costs relative to hospital treatment, even while its supply chain and administrative burden become harder to manage.
Home parenteral nutrition costs and access
Home parenteral nutrition is the clearest economics story in the dataset. The NHIA white paper shows a service delivered at scale, with costs moving in different directions depending on which part of the system you look at.
The most important comparison is straightforward: home parenteral nutrition reduced direct costs by 32% to 36% over 1 week to 1 month compared with hospital-based care (NHIA Home Parenteral Nutrition Cost White Paper). That finding matters because it frames HPN as a lower-direct-cost setting even before you account for nonclinical burden such as travel, caregiver time, or inpatient occupancy.
At the same time, delivery costs are not static. The same white paper reports that the compounded average cost to prepare a bag of HPN rose 75.4% from 2016 to 2024 (NHIA Home Parenteral Nutrition Cost White Paper). That is a large increase over a long period, and it helps explain why home infusion stakeholders keep attention on reimbursement, pharmacy capacity, and supply stability.
Key cost signals
| Measure | Value | Source |
|---|---|---|
| Americans served annually | ~32,000 | NHIA Home Parenteral Nutrition Cost White Paper |
| Direct cost reduction vs hospital care | 32% to 36% | NHIA Home Parenteral Nutrition Cost White Paper |
| Compounded bag-prep cost increase | 75.4% | NHIA Home Parenteral Nutrition Cost White Paper |
| Total monthly payment change per patient | -5.47% | NHIA Home Parenteral Nutrition Cost White Paper |
| Annual decline in HPN claim-submitting pharmacies | 15.6% | NHIA Home Parenteral Nutrition Cost White Paper |
That table shows an unusual combination. The patient-level monthly payment fell slightly, while the underlying preparation cost of a bag rose sharply. Those two facts are not identical, but together they suggest cost pressure is being absorbed somewhere in the payment and delivery chain rather than disappearing.
The white paper also says NHIA collected cost data from up to 20 unique home infusion pharmacies each year from 2016 to 2024 and analyzed 930,000 bags of HPN over that span (NHIA Home Parenteral Nutrition Cost White Paper). That is a substantial operational sample, which makes the trend lines more useful for spotting durable shifts than for reading any one-year anomaly.
Why the cost gap matters
- Hospital-based PN generally ties the therapy to a higher-cost setting.
- Home PN can lower direct costs for a short treatment window, according to the NHIA white paper.
- Rising compounding costs create a mismatch between delivery savings and manufacturing expense.
- A shrinking set of pharmacies submitting claims can increase fragility even when patient demand remains steady.
The main takeaway is not that home therapy is cheap. It is that the economics of home therapy are favorable relative to inpatient treatment while the system supporting it is under pressure from inflation, reimbursement, and pharmacy participation.
Drug shortages and supply pressure
Drug shortage data gives the parenteral nutrition story a broader operational context. The FDA report to Congress shows a historical shortage peak of 251 new drug shortages in 2011, compared with 15 new drug shortages in 2024 (FDA Drug Shortages Report to Congress CY 2024). That decline is important, but it does not mean the supply picture is easy.
The same FDA report says CY 2024 posed challenges for drugs used to provide parenteral nutrition (FDA Drug Shortages Report to Congress CY 2024). In other words, the overall number of shortages was low by historical standards, but PN-relevant products still faced friction.
Shortage timeline
| Year | New drug shortages | Source |
|---|---|---|
| 2005 | 61 | FDA Drug Shortages Report to Congress CY 2024 |
| 2011 | 251 | FDA Drug Shortages Report to Congress CY 2024 |
| 2024 | 15 | FDA Drug Shortages Report to Congress CY 2024 |
The FDA report also gives a window into how shortage management works in practice:
- DSS received 2,367 Form FDA 483 reports in CY 2024 (FDA Drug Shortages Report to Congress CY 2024).
- FDA expedited review of 225 submissions in CY 2024 (FDA Drug Shortages Report to Congress CY 2024).
- FDA prioritized 20 inspections to address drug shortages in CY 2024 (FDA Drug Shortages Report to Congress CY 2024).
- FDA and DEA coordination included 90 outreach occasions regarding potential shortage situations in CY 2024 (FDA Drug Shortages Report to Congress CY 2024).
- FDA exercised regulatory flexibility and discretion in 107 instances, affecting 114 products (FDA Drug Shortages Report to Congress CY 2024).
Those figures show that shortage management is not passive. It is a continuous coordination problem, especially for therapies where even a temporary interruption can change patient management.
Clinical dosing and nutrition benchmarks
The dataset includes several dosing and nutrition recommendations that are useful as reference points rather than as universal prescriptions. They show how tightly PN is tied to age, setting, and clinical goal.
For preterm infants, ASPEN recommends prompt initiation of PN as soon as appropriate vascular access is obtained after birth (ASPEN Parenteral Nutrition in Preterm Infants). The same source recommends against an initial parenteral amino acid dose above 3 g/kg/day, while also recommending a minimum dose of 3 g/kg/day and not exceeding 3.5 g/kg/day in preterm infants (ASPEN Parenteral Nutrition in Preterm Infants). Those numbers define a narrow therapeutic band.
ASPEN also recommends daily advancement of intravenous lipid emulsion to 3 g/kg/day when using soybean-oil ILE or multicomponent ILE in preterm infants, and it does not recommend a specific ILE composition for enhanced growth (ASPEN Parenteral Nutrition in Preterm Infants). That signals a preference for cautious advancement without overclaiming that one lipid formulation solves every problem.
Preterm PN reference points
| Topic | Recommendation | Source |
|---|---|---|
| Amino acids, initial dose | Do not exceed 3 g/kg/day | ASPEN Parenteral Nutrition in Preterm Infants |
| Amino acids, minimum dose | 3 g/kg/day | ASPEN Parenteral Nutrition in Preterm Infants |
| Amino acids, upper limit | 3.5 g/kg/day | ASPEN Parenteral Nutrition in Preterm Infants |
| Lipid advancement | 3 g/kg/day | ASPEN Parenteral Nutrition in Preterm Infants |
| Standardized PN solutions | Not recommended for routine care | ASPEN Parenteral Nutrition in Preterm Infants |
The same source says ASPEN recommends micronutrient provision, including calcium and phosphate, in line with consensus doses from ASPEN and ESPGHAN, and it recommends against routine insulin use to improve growth outcomes in hospitalized preterm infants (ASPEN Parenteral Nutrition in Preterm Infants). It also does not recommend reducing amino acids, dextrose, or ILE routinely to prevent PNALD, and it recommends against reducing ILE dose to prevent sepsis in preterm infants (ASPEN Parenteral Nutrition in Preterm Infants).
The nutrition requirements guidance adds another layer. It states that typical preterm ILE daily requirement is 1 to 3 g/kg/day, with some select clinical circumstances allowing up to 4 g/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant). Human milk fat provides about 40% to 50% of its energy from fat, and preterm feeding should provide 5 to 7 g of fat per kg per day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
Other numeric benchmarks in that source include:
- Enteral protein recommendation: 3.5 to 4.0 g/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
- ARA and DHA supplementation: 2:1 ratio (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
- Zinc: 300 mcg/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
- Copper: 20 mcg/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
- Manganese: 1 mcg/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
- Selenium: 2 mcg/kg/day (ASPEN Nutrition Requirements and Feeding Issues for the Preterm Infant).
For the ICU setting, ESPEN guidance in the dataset recommends 25 kcal/kg/day when indirect calorimetry is unavailable, a minimal carbohydrate requirement of about 2 g/kg glucose per day, and IV lipid emulsion infusion of 0.7 to 1.5 g/kg over 12 to 24 hours (Parenteral nutrition: Revisited, PMC). It also recommends balanced amino acids at approximately 1.3 to 1.5 g/kg ideal body weight per day (Parenteral nutrition: Revisited, PMC).
These values are useful because they show how PN targets are usually built from structured dose ranges rather than one universal number. They also show how deeply context-driven the keyword is: preterm care, adult ICU care, and home nutrition all operate under different numeric guardrails.
Infection and complication data
Safety data is one of the most practical parts of the dataset because catheter infections can drive avoidable readmissions, higher costs, and therapy interruptions.
The Sustain registry included 1,046 HPN patients from 29 U.S. sites (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain). It recorded 194 CLABSI events over 223,493 days of HPN exposure, with an overall CLABSI rate of 0.87 episodes per 1,000 PN-days (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
That is the most important benchmark in the infection section because it provides a broad registry-level rate for home therapy. The same registry also shows how risk is not evenly distributed:
- Men had 0.69 CLABSI episodes per 1,000 PN-days versus 0.38 for women (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
- Children had 1.17 versus 0.35 for adults (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
- Black patients had 0.91 versus 0.41 in non-Black patients (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
- Medicaid recipients had 1.0 versus 0.38 or 0.39 in other payer groups (Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain).
Infection context in one table
| Dataset | Population | Infection metric | Source |
|---|---|---|---|
| Sustain registry | 1,046 HPN patients | 0.87 CLABSI per 1,000 PN-days | Central venous catheter infections in home parenteral nutrition patients: Outcomes from Sustain |
| Regional HPN program | Home PN patients | 2.0 BSI per 1,000 catheter days | Epidemiology and risk factors for bloodstream infections in a home parenteral nutrition program |
| Regional HPN program, adjusted | Low-significance cultures excluded | 1.4 BSI per 1,000 catheter days | Epidemiology and risk factors for bloodstream infections in a home parenteral nutrition program |
| Meta-analysis | Home PN patients | 0.85 CRBSI per 1,000 catheter days | Epidemiology of Infectious and Noninfectious Catheter Complications in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Meta-Analysis |
| Meta-analysis | Home PN patients | 1.65 CLABSI per 1,000 catheter days | Epidemiology of Infectious and Noninfectious Catheter Complications in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Meta-Analysis |
That table is useful because it places multiple infection benchmarks side by side without pretending they are identical. The rates come from different study designs and populations, but together they show that infection risk is measurable, persistent, and highly relevant to the economics of HPN.
A hospitalized PN cohort reported a catheter-related infection rate of 25 per 1,000 days of PTN (Incidence of catheter-related infection and associated risk factors in hospitalized patients with parenteral nutrition). That same cohort included 271 patients followed for 6 months and reported 10.4% mortality (Incidence of catheter-related infection and associated risk factors in hospitalized patients with parenteral nutrition). Hospital PN therefore appears in the dataset as a setting with different operational risks than home therapy, which reinforces why route and context matter.
Home-start and hospital-use patterns
The home-start abstract gives a practical picture of who receives PN at home and how their therapy is organized. It studied 109 adult patients over a 12-month period (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
The case mix was diverse:
- 36% oncology patients (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 35% GI patients (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 16% bariatric patients (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 8% with hyperemesis gravidarum (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
Therapy management was also heavily protocolized:
- 71% of PN dosing recommendations were managed by the HNST (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 56% were at significant refeeding-syndrome risk (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 34% had electrolyte abnormalities before PN start (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 27% received IV hydration before PN start (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 89% received custom PN, while 11% received commercially available multi-chamber bag PN (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 100% received IV multivitamins, averaging 5 days per week because of shortage constraints (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- 88% received IV thiamin at at least 100 mg/day (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
- No hospitalizations due to PN complications occurred during the first week of home-initiated therapy in that abstract (Initiating parenteral nutrition in the home: a snapshot of dosing practices).
Those are useful operational facts because they show how home initiation depends on pre-planning, pharmacy format, and micronutrient substitution when supply constraints appear.
Practical reading of the dataset
- Home PN is not niche in the narrow sense; it serves tens of thousands of Americans annually (NHIA Home Parenteral Nutrition Cost White Paper).
- The economics favor home care relative to hospital-based care on direct costs, but the production side is getting more expensive (NHIA Home Parenteral Nutrition Cost White Paper).
- Shortages and supply controls still matter even when the overall shortage count is lower than past peaks (FDA Drug Shortages Report to Congress CY 2024).
- Infection benchmarks vary across datasets, but the rates are high enough to remain a central quality metric for any home PN program (Sustain registry; meta-analysis; regional HPN program).
- Preterm and ICU guidance uses narrow dose ranges, which reflects how much the therapy depends on patient condition rather than a one-size-fits-all rule (ASPEN and ESPEN sources).
Why it matters for patients and providers
Parenteral nutrition statistics are most useful when they help separate three different questions: how much the therapy costs, how safely it is delivered, and how carefully it must be dosed. This dataset gives a number for each of those layers.
The cost story says home PN can reduce direct expenses versus hospital care, even as compounding and claim-side pressures rise (NHIA Home Parenteral Nutrition Cost White Paper). The safety story says infection rates are low enough to be manageable but high enough to shape outcomes and payer attention (Sustain registry; meta-analysis; regional HPN program). The clinical story says dosing is highly specific, especially for preterm infants and ICU patients (ASPEN; ESPEN).
What makes the keyword especially search-worthy is that it pulls all of that into one place. Readers looking for parenteral nutrition statistics are usually trying to understand a clinical service that is expensive, vulnerable to shortages, and tightly regulated by dose and access constraints. The numbers in this dataset make that picture concrete.